Contingency Management Is Coming to Medicaid — and It Could Change Everything for Methamphetamine Recovery

For decades, the treatment gap for people using methamphetamine or cocaine has been an open wound in American public health. No FDA-approved medication exists for stimulant use disorder. Behavioral treatments work — but cost money that Medicaid historically would not cover.

That is starting to change. Five states — California, Delaware, Hawaii, Montana, and Washington — now offer Medicaid-covered contingency management (CM) for stimulant use disorder. Two more states (Michigan and Rhode Island) have pending applications at CMS. If approved, coverage could reach 26% of all Medicaid enrollees with a diagnosed stimulant use disorder nationally.

What Contingency Management Actually Is

Contingency management works on a deceptively simple principle: provide immediate, tangible rewards for verifiable non-use of a substance. A person with meth use disorder comes in twice weekly, submits a urine test, and if results are negative, receives a prize, voucher, gift card, or small cash incentive. State programs run 12-week interventions; enrollees can receive between $596 and $1,092 in incentives over the course.

CM is the most rigorously studied behavioral intervention for stimulant use disorder, with dozens of randomized controlled trials across thirty years. The science is not disputed — it has been replicated across populations, settings, and substances.

Why It Took So Long

CM does not fit neatly into existing Medicaid billing frameworks. States had to use Section 1115 demonstration waivers to carve out coverage. Each waiver requires a lengthy federal review, state actuarial analysis, and CMS approval. The stigma factor also matters: the idea of paying people not to use drugs generated political resistance that had almost nothing to do with the evidence.

The Medication Gap

Unlike opioid use disorder — where methadone, buprenorphine, and naltrexone are effective and FDA-approved — there is still no approved pharmacotherapy for methamphetamine or cocaine use disorder. The combination of bupropion + naltrexone has shown promise in NIDA Clinical Trials Network studies and is in Phase 2/3 trials (NCT06233799). But drug development takes time — and time kills. CM is, right now, the best thing we have.

What Is Still Missing

Coverage in five states is not a solution. Most of the South, Midwest, and Mountain West — regions with the highest meth use rates — have no approved CM coverage. Arizona specifically does not have an approved Medicaid CM program. The incentive cap ($599 in many states) is a policy compromise, not an evidence-based threshold. Provider training remains a significant gap.

Why This Matters for People in Recovery

If you or someone you love is struggling with methamphetamine or cocaine use, contingency management may be available in your state. In California, Delaware, Hawaii, Montana, and Washington, it is now Medicaid-covered. The Rize platform connects people with treatment facilities that offer evidence-based behavioral programs, including contingency management where available. Start here to find options near you.